Mid-tier pharma mergers and a shift to more complex trials will benefit broad-based CROs, whilst smaller outsourcing partners will be forced to consolidate, an industry report by Citi Research predicts.
Charles River Laboratories says it will shutter a Research Models and Services (RMS) facility in Michigan as softened demand for the sector offset a strong year for its preclinical service business.
Catalent has filed an initial public offering (IPO) with the SEC to raise $100m though this could reach upwards of $500m, according to one investment firm.
Whether McKesson will relaunch its bid to acquire German logistics firm Celsio has been questioned by analysts after the proposed $8.3bn (€6.1bn) takeover bid fell through.
Patheon is the world’s largest pharmaceutical development services (PDS) provider and third largest contract manufacturer, according to a report released yesterday.
Algorithme Pharma has increased early stage patient access by teaming with a Montreal hospital, and says it provides a breadth of therapeutic areas not normally associated with mid-sized CROs.
Soon to merge CMO Patheon has increased solid dosage form production capacity at its site in the UK and posted an improved set of preliminary results for the financial year.
Trust, transparency and end-to-end participation are just some of the reasons Merck Serono says its exclusive strategic partnership with Quintiles is the “first of its kind.”
Strategic partnerships are “the next phase” of sponsor-CRO relations, according to Parexel, and on top of saving pharma on oversight costs will reshape the industry.
inVentiv Health has opened a new UK office in order to better target European customers, whilst Novum says its North Dakota facility will strengthen its offerings.
Sponsor network developer DrugDev on Monday announced it would acquire CFS Clinical, which specializes in managing the financing of clinical trials. Financial terms were not disclosed.
McKesson Corporation who is said to be in talks to acquire German logistics company Celesio has appointed a new CFO and Executive Director - Welcome to Outsourcing-Pharma's People on the Move.
AAIPharma says the merger with Cambridge Major Laboratories (CML) will bring clients the benefits of integrated Chemistry and Manufacturing Controls (CMC) services from two high-growth CMOs.
Molecular Profiles has been chosen to develop topical and solid dose formulations of a preclinical psoriasis treatment as part of a multicompany conglomerate led by Telormedix.
The CMO market remains highly fragmented with thirty percent of active players likely to exit the business in the next ten years, according to a Frost & Sullivan report.
US CRO Crown BioSciences has acquired Precos citing the UK contractor’s preclinical oncology services and presence in the European market as the key drivers.
Clinical Research Advantage (CRA) has acquired the late phase business of Comprehensive Clinical Development (CCD) adding psychiatric clinical trials to its services.
A new personalised medicine-focused partnership for AstraZeneca, expansion in three continents for World Wide clinical and six small CROs team-up to create one super-team. Outsourcing-pharma.com presents a round-up of the latest in clinical research services.
Piramal Healthcare wants to add sterile injectables to its offering but is unwilling to overpay for facilities owned by 'value focused' private equity groups.
Health economics and outcomes research teams must have a greater influence over clinical trial design if pharma firms are to achieve reimbursement goals, according to Cutting Edge Information.
Outsourcing-Pharma.com presents the low down on new services forged by partnerships and M&A (mergers and acquisitions), including a molecular biology offering for Quotient, Onyx’s added purification and separation capabilities, and Accenture’s new...
